Abstract

Background:Breast cancer is a heterogeneous disease that can be subdivided on the basis of histopathological features, genetic alterations, and gene-expression profiles. PTEN gene is considered an established tumor suppressor gene in different types of cancer including breast cancer. However, the role of PTEN alterations in north Indian breast cancer has not been explored especially in defining a group with distinct histological factors.Methodology:181 sporadic breast cancer and their adjacent normal tissues were included in the present study. We analyzed methylation and LOH through MS-PCR and microsatellite markers respectively. While, for PTEN protein expression, we used immunohistochemistry. All the molecular findings were correlated with the clinicopathological parameters of the patients to underline clinical relevance.Results:We found that LOH and methylation of the PTEN promoter were significantly associated with loss of PTEN protein expression, while, PTEN mutation was a rare event. Furthermore, out of 46 double hit cases (i.e., having both methylation and LOH), 70% (32/46) cases showed complete loss of PTEN expression (P= 0.0249). Both LOH and PTEN promoter methylation were associated significantly with age and clinical stage, while, methylation and loss of PTEN expression were associated with high grade and Her-2 negativity. In addition, a quadruple (ER/PR/Her-2 and PTEN) negative group with distinct features was found.Conclusion:The pattern of PTEN expression and its correlation with the clinical parameters indicates that loss of PTEN expression defines a clinical group with distinct features. Hence, PTEN expression provides differential therapeutic strategies for north Indian breast cancer.

Highlights

  • Breast cancer is the most frequent cause of cancer-related death among women worldwide, claiming more than 400,000 lives every year (Jemal et al, 2011)

  • We found that Loss of heterozygosity (LOH) and methylation of the PTEN promoter were significantly associated with loss of PTEN protein expression, while, PTEN mutation was a rare event

  • We further analyzed how different molecular aberrations of the PTEN gene are correlated with different clinicopathological parameters and define subgroups among north Indian breast cancer patients

Read more

Summary

Introduction

Breast cancer is the most frequent cause of cancer-related death among women worldwide, claiming more than 400,000 lives every year (Jemal et al, 2011). PTEN (Phosphatase and tensin homolog) gene, located on chromosome 10 is a well-known tumor suppressor gene, which is frequently altered in a wide spectrum of cancers (Li et al, 1997; Steck et al, 1997). Results: We found that LOH and methylation of the PTEN promoter were significantly associated with loss of PTEN protein expression, while, PTEN mutation was a rare event. Out of 46 double hit cases (i.e., having both methylation and LOH), 70% (32/46) cases showed complete loss of PTEN expression (P= 0.0249). PTEN expression provides differential therapeutic strategies for north Indian breast cancer

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call